PL2702155T3 - Związki mikroRNA i sposoby modulowania aktywności miR-21 - Google Patents

Związki mikroRNA i sposoby modulowania aktywności miR-21

Info

Publication number: PL2702155T3
Authority: PL; Poland
Prior art keywords: activity; methods; modulating mir; microrna compounds; microrna
Prior art date: 2011-04-25

Application number

PL12718549T

Other languages

English (en)

Inventor

Balkrishen Bhat

Original Assignee

Regulus Therapeutics Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-25

Filing date

2012-04-25

Publication date

2017-09-29

2012-04-25 Application filed by Regulus Therapeutics Inc. filed Critical Regulus Therapeutics Inc.

2017-09-29 Publication of PL2702155T3 publication Critical patent/PL2702155T3/pl

Links

150000001875 compounds Chemical class 0.000 title 1
108091062762 miR-21 stem-loop Proteins 0.000 title 1
108091041631 miR-21-1 stem-loop Proteins 0.000 title 1
108091044442 miR-21-2 stem-loop Proteins 0.000 title 1
108091070501 miRNA Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Hematology (AREA)
Oncology (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Immunology (AREA)
Pulmonology (AREA)

PL12718549T 2011-04-25 2012-04-25 Związki mikroRNA i sposoby modulowania aktywności miR-21 PL2702155T3 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161478767P	2011-04-25	2011-04-25
US201161565779P	2011-12-01	2011-12-01

Publications (1)

Publication Number	Publication Date
PL2702155T3 true PL2702155T3 (pl)	2017-09-29

Family

ID=46025979

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL12718549T PL2702155T3 (pl)	2011-04-25	2012-04-25	Związki mikroRNA i sposoby modulowania aktywności miR-21
PL17153724T PL3211082T3 (pl)	2011-04-25	2012-04-25	Związki mikroRNA i sposoby modulowania aktywności miR-21

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL17153724T PL3211082T3 (pl)	2011-04-25	2012-04-25	Związki mikroRNA i sposoby modulowania aktywności miR-21

Country Status (30)

Country	Link
US (7)	US9181547B2 (pl)
EP (3)	EP3933040A1 (pl)
JP (2)	JP6320292B2 (pl)
KR (2)	KR20190063482A (pl)
CN (3)	CN113151272A (pl)
AU (4)	AU2012249851B2 (pl)
BR (1)	BR112013027187A2 (pl)
CA (2)	CA3165397A1 (pl)
CL (1)	CL2013003105A1 (pl)
CO (1)	CO6821889A2 (pl)
CY (1)	CY1120304T1 (pl)
DK (2)	DK3211082T3 (pl)
EA (1)	EA025894B1 (pl)
ES (2)	ES2868950T3 (pl)
HR (2)	HRP20170557T2 (pl)
HU (2)	HUE054129T2 (pl)
IL (3)	IL229032B (pl)
LT (2)	LT3211082T (pl)
MX (5)	MX393138B (pl)
MY (2)	MY187685A (pl)
NZ (1)	NZ717921A (pl)
PH (1)	PH12013502199A1 (pl)
PL (2)	PL2702155T3 (pl)
PT (2)	PT3211082T (pl)
RS (1)	RS61775B1 (pl)
SG (1)	SG194636A1 (pl)
SI (2)	SI2702155T1 (pl)
TW (2)	TWI607016B (pl)
UA (1)	UA115652C2 (pl)
WO (1)	WO2012148952A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2534300T3 (es)	2004-11-12	2015-04-21	Asuragen, Inc.	Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
MX393138B (es)	2011-04-25	2025-03-24	Sanofi Sa	Compuestos de microarn y metodos para modular la actividad de mir-21.
US9193971B2 (en) *	2012-04-10	2015-11-24	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Methods for the treatment of nonalcoholic steatohepatitis
MY173600A (en)	2012-04-25	2020-02-08	Sanofi Sa	Microrna compounds and methods for modulating mir-21 activity
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта
CA2889044A1 (en)	2012-11-15	2014-05-22	Roche Innovation Center Copenhagen A/S	Anti apob antisense conjugate compounds
JP2016518842A (ja)	2013-05-01	2016-06-30	レグルスセラピューティクスインコーポレイテッド	マイクロＲＮＡ化合物およびｍｉＲ−１２２をモジュレートする方法
WO2015061536A1 (en) *	2013-10-25	2015-04-30	Regulus Therapeutics Inc.	Microrna compounds and methods for modulating mir-21 activity
KR101625755B1 (ko)	2013-11-18	2016-05-30	울산대학교 산학협력단	ｍｉＲＮＡ 스폰지 및 이의 용도
US10358643B2 (en) *	2014-01-30	2019-07-23	Hoffmann-La Roche, Inc.	Poly oligomer compound with biocleavable conjugates
CN105734127A (zh) *	2016-02-29	2016-07-06	上海中医药大学	miR-21-3p在制备用于检测早期急性肾损伤的试剂中的用途
EP3449001B1 (en) *	2016-04-29	2021-12-08	Aptamir Therapeutics, Inc.	Inhibition of mir-22 mirna by apt-110
US20180193270A1 (en)	2016-11-29	2018-07-12	PureTech Health LLC	Exosomes for delivery of therapeutic agents
DK3684949T3 (en)	2017-09-22	2024-07-08	Univ Washington	In situ combinatorial labeling of cellular molecules
CN108148911B (zh) *	2018-03-02	2019-11-05	广州医科大学附属第二医院	miR-582在制备前列腺癌骨转移的诊断、预后试剂盒及药物中的应用
TWI854980B (zh)	2018-05-08	2024-09-11	美商雷格勒斯治療公司	用於調節mir-122之微小rna化合物及方法
CN110747266A (zh) *	2018-07-23	2020-02-04	深圳先进技术研究院	miR-21和miR-21拮抗剂在抑制预防/治疗1型糖尿病中的应用
CN109880907A (zh) *	2019-03-26	2019-06-14	中国人民解放军第八一医院	一种肝癌细胞侵袭转移的分子机制研究方法
US11965162B2 (en)	2020-04-16	2024-04-23	The Johns Hopkins University	MicroRNA and inhibitors thereof and methods of treatment
WO2022165092A1 (en) *	2021-01-29	2022-08-04	Angion Biomedica Corp.	Methods for treatment of fibrotic diseases
CN122295113A (zh) *	2023-11-22	2026-06-26	国立大学法人东海国立大学机构	囊性肾病的预防和/或治疗剂
CN120505413A (zh) *	2025-07-15	2025-08-19	湖南工程学院	一种基于引物交换反应和G-四链体检测AKI相关miRNA的探针体系及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2285841T3 (es)	1998-05-22	2007-11-16	Boys Town National Research Hospital	Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal.
US20060008817A1 (en) *	2000-12-08	2006-01-12	Invitrogen Corporation	Methods and compositions for generating recombinant nucleic acid molecules
EP2428570B1 (en)	2001-09-28	2018-05-23	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.	Microrna molecules
CA2504694C (en)	2002-11-05	2013-10-01	Isis Pharmaceuticals, Inc.	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050124591A1 (en)	2003-07-29	2005-06-09	Jin Tian	Use of vitamin Ds to treat kidney disease
WO2005013901A2 (en) *	2003-07-31	2005-02-17	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK1661905T3 (da)	2003-08-28	2012-07-23	Takeshi Imanishi	Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
EP2990410A1 (en)	2004-08-10	2016-03-02	Alnylam Pharmaceuticals Inc.	Chemically modified oligonucleotides
US20080187508A1 (en)	2004-09-08	2008-08-07	Boys Town National Research Hospital	Treatment of Golmerular Basement Membrane Disease Involving Matrix Metalloproteinase-12
ES2534300T3 (es)	2004-11-12	2015-04-21	Asuragen, Inc.	Procedimientos y composiciones que implican miARN y moléculas inhibidoras de miARN
US20070099196A1 (en)	2004-12-29	2007-05-03	Sakari Kauppinen	Novel oligonucleotide compositions and probe sequences useful for detection and analysis of micrornas and their target mRNAs
US6995235B1 (en)	2005-05-02	2006-02-07	Univation Technologies, Llc	Methods of producing polyolefins and films therefrom
WO2007027894A2 (en) *	2005-08-29	2007-03-08	Isis Pharmaceuticals, Inc.	Antisense compounds having enhanced anti-microrna activity
DE602007009487D1 (de)	2006-01-27	2010-11-11	Isis Pharmaceutical Inc	6-modifizierte bicyclische nukleinsäureanaloga
EP2388328A1 (en)	2006-01-27	2011-11-23	Isis Pharmaceuticals, Inc.	Oligomeric compounds and compositions for the use in modulation of micrornas
CA3042781C (en)	2006-04-03	2021-10-19	Roche Innovation Center Copenhagen A/S	Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EA201100811A1 (ru) *	2006-04-03	2012-06-29	Сантарис Фарма А/С	Фармацевтическая композиция
CA3144493A1 (en)	2006-10-03	2008-04-10	Arbutus Biopharma Corporation	Lipid containing formulations
JP2010505427A (ja)	2006-10-09	2010-02-25	ジュリアス−マキシミリアンズ−ユニベルシタットワーズブルグ	心疾患の診断及び治療用マイクロＲＮＡ（ｍｉＲＮＡ）
EP2104735A2 (en)	2006-12-08	2009-09-30	Asuragen, INC.	Mir-21 regulated genes and pathways as targets for therapeutic intervention
WO2008086807A2 (en)	2007-01-19	2008-07-24	Exiqon A/S	Mediated cellular delivery of lna oligonucleotides
DK2170917T3 (da)	2007-05-30	2012-10-08	Isis Pharmaceuticals Inc	N-Substituerede bicycliske nukleinsyreanaloge med aminomethylenbro
WO2008154401A2 (en)	2007-06-08	2008-12-18	Isis Pharmaceuticals, Inc.	Carbocyclic bicyclic nucleic acid analogs
US20100261175A1 (en)	2007-06-15	2010-10-14	Exiqon A/S	Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
AU2008272918B2 (en)	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
DK2205737T3 (da) *	2007-10-04	2013-05-21	Santaris Pharma As	Mikromirer
CN101980712B (zh)	2007-10-29	2015-02-18	雷古拉斯治疗公司	用于肝癌治疗的靶向微小rna
WO2009091972A2 (en)	2008-01-18	2009-07-23	Alnylam Pharmaceuticals, Inc.	Chemically modified oligonucleotides and small molecules for use in reducing micro rna activity levels and uses thereof
JP2011510678A (ja)	2008-02-08	2011-04-07	プロセンサホールディングビーブイ	Ｄｎａ反復不安定性関連遺伝性障害を治療するための方法及び手段
EP2096171A1 (en) *	2008-02-27	2009-09-02	Julius-Maximilians-Universität Würzburg	MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes
EP2268811A1 (en)	2008-03-07	2011-01-05	Santaris Pharma A/S	Pharmaceutical compositions for treatment of microrna related diseases
JP2012518997A (ja) *	2009-02-26	2012-08-23	ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション	喫煙未経験者におけるマイクロｒｎａ、ならびに関連する材料および方法
MA33488B1 (fr) *	2009-06-08	2012-08-01	Miragen Therapeutics	Motifs de modification chimique pour des inhibiteurs et mimétiques de miarn
WO2011126842A2 (en)	2010-03-30	2011-10-13	Regulus Therapeutics Inc.	Targeting micrornas for the treatment of cardiac disorders
MX393138B (es)	2011-04-25	2025-03-24	Sanofi Sa	Compuestos de microarn y metodos para modular la actividad de mir-21.
WO2013013165A2 (en)	2011-07-21	2013-01-24	The Trustees Of The University Of Pennsylvania	Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus
MY173600A (en)	2012-04-25	2020-02-08	Sanofi Sa	Microrna compounds and methods for modulating mir-21 activity
EP2864482A4 (en)	2012-06-21	2016-02-10	Miragen Therapeutics Inc	OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
CN104955950B (zh)	2012-09-26	2019-04-26	米尔克斯治疗学公司	具有改善的脱靶特征谱的寡核苷酸
UA116639C2 (uk)	2012-10-09	2018-04-25	Рег'Юлес Терап'Ютікс Інк.	Способи лікування синдрому альпорта

2012
- 2012-04-25 MX MX2019003090A patent/MX393138B/es unknown
- 2012-04-25 JP JP2014508494A patent/JP6320292B2/ja active Active
- 2012-04-25 NZ NZ717921A patent/NZ717921A/en unknown
- 2012-04-25 ES ES17153724T patent/ES2868950T3/es active Active
- 2012-04-25 DK DK17153724.4T patent/DK3211082T3/da active
- 2012-04-25 PT PT171537244T patent/PT3211082T/pt unknown
- 2012-04-25 MY MYPI2017000706A patent/MY187685A/en unknown
- 2012-04-25 PL PL12718549T patent/PL2702155T3/pl unknown
- 2012-04-25 ES ES12718549.4T patent/ES2621863T3/es active Active
- 2012-04-25 DK DK12718549.4T patent/DK2702155T3/en active
- 2012-04-25 EA EA201391492A patent/EA025894B1/ru not_active IP Right Cessation
- 2012-04-25 UA UAA201312414A patent/UA115652C2/uk unknown
- 2012-04-25 US US14/111,976 patent/US9181547B2/en active Active
- 2012-04-25 CN CN202110384864.8A patent/CN113151272A/zh active Pending
- 2012-04-25 KR KR1020197015054A patent/KR20190063482A/ko not_active Ceased
- 2012-04-25 MY MYPI2013003885A patent/MY175336A/en unknown
- 2012-04-25 PL PL17153724T patent/PL3211082T3/pl unknown
- 2012-04-25 CN CN202110383567.1A patent/CN113249381A/zh active Pending
- 2012-04-25 RS RS20210552A patent/RS61775B1/sr unknown
- 2012-04-25 CA CA3165397A patent/CA3165397A1/en active Pending
- 2012-04-25 EP EP21157334.0A patent/EP3933040A1/en not_active Withdrawn
- 2012-04-25 EP EP12718549.4A patent/EP2702155B9/en active Active
- 2012-04-25 BR BR112013027187A patent/BR112013027187A2/pt not_active Application Discontinuation
- 2012-04-25 SI SI201230924A patent/SI2702155T1/sl unknown
- 2012-04-25 TW TW101114636A patent/TWI607016B/zh active
- 2012-04-25 CN CN201280031285.4A patent/CN103620035B/zh active Active
- 2012-04-25 AU AU2012249851A patent/AU2012249851B2/en active Active
- 2012-04-25 TW TW106131684A patent/TWI698445B/zh active
- 2012-04-25 EP EP17153724.4A patent/EP3211082B1/en active Active
- 2012-04-25 LT LTEP17153724.4T patent/LT3211082T/lt unknown
- 2012-04-25 KR KR1020137031227A patent/KR102055172B1/ko active Active
- 2012-04-25 CA CA2833615A patent/CA2833615C/en active Active
- 2012-04-25 PT PT127185494T patent/PT2702155T/pt unknown
- 2012-04-25 LT LTEP12718549.4T patent/LT2702155T/lt unknown
- 2012-04-25 HU HUE17153724A patent/HUE054129T2/hu unknown
- 2012-04-25 US US13/455,337 patent/US20120270928A1/en active Pending
- 2012-04-25 WO PCT/US2012/034880 patent/WO2012148952A1/en not_active Ceased
- 2012-04-25 MX MX2013012452A patent/MX2013012452A/es unknown
- 2012-04-25 PH PH1/2013/502199A patent/PH12013502199A1/en unknown
- 2012-04-25 SG SG2013079454A patent/SG194636A1/en unknown
- 2012-04-25 SI SI201231913T patent/SI3211082T1/sl unknown
- 2012-04-25 HR HRP20170557TT patent/HRP20170557T2/hr unknown
- 2012-04-25 HU HUE12718549A patent/HUE031595T2/en unknown
2013
- 2013-10-23 MX MX2019003089A patent/MX2019003089A/es unknown
- 2013-10-23 MX MX2022000212A patent/MX2022000212A/es unknown
- 2013-10-23 IL IL229032A patent/IL229032B/en active IP Right Grant
- 2013-10-23 MX MX2022006595A patent/MX2022006595A/es unknown
- 2013-10-25 CL CL2013003105A patent/CL2013003105A1/es unknown
- 2013-10-30 CO CO13257480A patent/CO6821889A2/es unknown
2014
- 2014-07-28 US US14/444,406 patent/US8912161B2/en active Active
2015
- 2015-10-14 US US14/883,055 patent/US9790496B2/en active Active
2017
- 2017-04-25 CY CY20171100460T patent/CY1120304T1/el unknown
- 2017-08-29 AU AU2017219156A patent/AU2017219156B2/en active Active
- 2017-09-14 US US15/704,749 patent/US20180155719A1/en not_active Abandoned
2018
- 2018-04-02 JP JP2018070694A patent/JP2018121646A/ja active Pending
2019
- 2019-05-08 IL IL266529A patent/IL266529A/en unknown
2020
- 2020-01-24 US US16/751,402 patent/US20200291400A1/en not_active Abandoned
- 2020-02-26 AU AU2020201403A patent/AU2020201403A1/en not_active Abandoned
- 2020-03-18 IL IL273381A patent/IL273381A/en unknown
2021
- 2021-04-19 HR HRP20210616TT patent/HRP20210616T1/hr unknown
- 2021-08-18 US US17/405,482 patent/US12331294B2/en active Active
2022
- 2022-05-06 AU AU2022203067A patent/AU2022203067A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2018121646A (ja)	2018-08-09
CY1120304T1 (el)	2019-07-10
US8912161B2 (en)	2014-12-16
US9181547B2 (en)	2015-11-10
LT2702155T (lt)	2017-05-10
EP3933040A1 (en)	2022-01-05
AU2012249851B2 (en)	2017-06-08
AU2012249851A8 (en)	2013-11-14
SI2702155T1 (sl)	2017-07-31
KR20190063482A (ko)	2019-06-07
US20220098583A1 (en)	2022-03-31
CN113249381A (zh)	2021-08-13
US9790496B2 (en)	2017-10-17
MY187685A (en)	2021-10-11
MX2022000212A (es)	2022-04-01
JP6320292B2 (ja)	2018-05-09
MX2019003090A (es)	2019-07-18
US20180155719A1 (en)	2018-06-07
PL3211082T3 (pl)	2021-08-02
IL273381A (en)	2020-05-31
NZ616748A (en)	2016-03-31
EA025894B1 (ru)	2017-02-28
AU2017219156A1 (en)	2017-09-21
AU2020201403A1 (en)	2020-03-12
ES2621863T3 (es)	2017-07-05
EP2702155A1 (en)	2014-03-05
CN103620035B (zh)	2021-04-23
PT2702155T (pt)	2017-04-03
HRP20170557T1 (hr)	2017-06-16
IL229032A0 (en)	2013-12-31
EA201391492A1 (ru)	2014-04-30
IL266529A (en)	2019-07-31
SG194636A1 (en)	2013-12-30
EP3211082B1 (en)	2021-02-17
PH12013502199A1 (en)	2014-01-27
EP2702155B1 (en)	2017-02-01
HK1243130A1 (en)	2018-07-06
AU2017219156B2 (en)	2020-01-02
EP3211082A1 (en)	2017-08-30
CA3165397A1 (en)	2012-11-01
TW201300404A (zh)	2013-01-01
BR112013027187A2 (pt)	2017-06-06
KR20140033062A (ko)	2014-03-17
MY175336A (en)	2020-06-19
CN113151272A (zh)	2021-07-23
LT3211082T (lt)	2021-05-10
MX2019003089A (es)	2019-07-18
TWI607016B (zh)	2017-12-01
AU2022203067A1 (en)	2022-05-26
SI3211082T1 (sl)	2021-08-31
US20120270928A1 (en)	2012-10-25
US20160138016A1 (en)	2016-05-19
DK2702155T3 (en)	2017-05-01
MX393138B (es)	2025-03-24
TWI698445B (zh)	2020-07-11
HRP20170557T2 (hr)	2020-02-21
WO2012148952A1 (en)	2012-11-01
EP2702155B9 (en)	2020-01-01
KR102055172B1 (ko)	2020-01-23
MX2013012452A (es)	2014-11-21
AU2012249851A1 (en)	2013-10-31
CL2013003105A1 (es)	2014-08-01
DK3211082T3 (da)	2021-05-10
CO6821889A2 (es)	2013-12-31
IL229032B (en)	2021-01-31
TW201811812A (zh)	2018-04-01
CA2833615C (en)	2022-08-30
US20140107183A1 (en)	2014-04-17
CN103620035A (zh)	2014-03-05
JP2014518619A (ja)	2014-08-07
UA115652C2 (uk)	2017-12-11
US20140329887A1 (en)	2014-11-06
ES2621863T9 (es)	2020-02-13
HRP20210616T1 (hr)	2021-05-28
MX2022006595A (es)	2022-07-01
RS61775B1 (sr)	2021-05-31
US12331294B2 (en)	2025-06-17
ES2868950T3 (es)	2021-10-22
CA2833615A1 (en)	2012-11-01
HUE054129T2 (hu)	2021-08-30
PT3211082T (pt)	2021-04-28
US20200291400A1 (en)	2020-09-17
HUE031595T2 (en)	2017-07-28
NZ717921A (en)	2017-09-29

Publication	Publication Date	Title
IL273381A (en)	2020-05-31	MicroRNA compounds and methods to modulate mir-21 activity
ZA201407228B (en)	2017-05-31	Microrna compounds and methods for modulating mir-21 activity
PT3636274T (pt)	2024-10-17	Composições para modular a atividade das citocinas gama-c
GB2528399B (en)	2016-03-02	Catalyst and method for its preparation
IL231800A0 (en)	2014-05-28	smoking system
IL228546A0 (en)	2013-12-31	fermentation process
GB201112231D0 (en)	2011-08-31	Micro-organism
SG11201403280PA (en)	2014-07-30	Bioreactor
IL229446A0 (en)	2014-01-30	Rolled collagen carrier
SG11201402144WA (en)	2014-09-26	Improved modulators of hec1 activity and methods therefor
EP2864469A4 (en)	2016-05-18	BIOREACTOR CARTRIDGE AND SYSTEM
IL228700A0 (en)	2013-12-31	A method for modulating cytokine activity
GB201108165D0 (en)	2011-06-29	Bioreactor chamber and method
GB201109849D0 (en)	2011-07-27	Modulation
AU2011011V (en)	2012-09-04	FFV1 Ficus obliqua
GB201111898D0 (en)	2011-08-24	Bioreactor chamber and method
GB201122254D0 (en)	2012-02-01	Bioreactor chamber and method
GB201105580D0 (en)	2011-05-18	Osteoclast activity
GB201105578D0 (en)	2011-05-18	Osteoclast activity
GB201105579D0 (en)	2011-05-18	Osteoclast activity